RESEARCH - CP-690,550, a JAK inhibitor, improved pain, physical functioning, and healh status in RA

[Guest guest]

Ann Rheum Dis 2010;69:413-416 doi:10.1136/ard.2009.108159

Clinical and epidemiological research

Concise report

Improved pain, physical functioning and health status in patients with

rheumatoid arthritis treated with CP-690,550, an orally active Janus

kinase (JAK) inhibitor: results from a randomised, double-blind,

placebo-controlled trial

J H Coombs1, B J Bloom2, F C Breedveld3, M P Fletcher1, D Gruben2, J M

Kremer4, R Burgos-Vargas5, B Wilkinson2, C A F Zerbini6, S H Zwillich1

+ Author Affiliations

1Pfizer Inc, Ann Arbor, Michigan, USA

2Pfizer Inc, New London, Connecticut, USA

3Leiden University Medical Centre, Leiden, The Netherlands

4Albany Medical College, Albany, New York, USA

5Hospital General de Mexico, Mexico City, Mexico

6Hospital Heliopolis, Sao o, Brazil

Abstract

Objectives: To determine the efficacy of CP-690,550 in improving pain,

function and health status in patients with moderate to severe active

rheumatoid arthritis (RA) and an inadequate response to methotrexate

or a tumour necrosis factor α inhibitor.

Methods: Patients were randomised equally to placebo, CP-690,550 5, 15

or 30 mg twice daily for 6 weeks, with 6 weeks’ follow-up. The

patient’s assessment of arthritis pain (pain), patient’s assessment of

disease activity, Health Assessment Questionnaire-Disability Index

(HAQ-DI) and Short Form-36 (SF-36) were recorded.

Results: At week 6, significantly more patients in the CP-690,550 5,

15 and 30 mg twice-daily groups experienced a 50% improvement in pain

compared with placebo (44%, 66%, 78% and 14%, respectively),

clinically meaningful reductions in HAQ-DI (≥0.3 units) (57%, 75%, 76%

and 36%, respectively) and clinically meaningful improvements in SF-36

domains and physical and mental components.

Conclusions: CP-690,550 was efficacious in improving the pain,

function and health status of patients with RA, from week 1 to week 6.

http://ard.bmj.com/content/69/2/413.abstract?etoc

Not an MD